HLA Stock Overview
Healthia Limited provides health services in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.47|
|52 Week High||AU$2.44|
|52 Week Low||AU$1.26|
|1 Month Change||-17.42%|
|3 Month Change||3.52%|
|1 Year Change||-18.79%|
|3 Year Change||68.97%|
|5 Year Change||n/a|
|Change since IPO||23.01%|
Recent News & Updates
|HLA||AU Healthcare||AU Market|
Return vs Industry: HLA exceeded the Australian Healthcare industry which returned -20% over the past year.
Return vs Market: HLA underperformed the Australian Market which returned -9.7% over the past year.
|HLA Average Weekly Movement||6.3%|
|Healthcare Industry Average Movement||5.4%|
|Market Average Movement||9.5%|
|10% most volatile stocks in AU Market||16.7%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: HLA is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: HLA's weekly volatility (6%) has been stable over the past year.
About the Company
Healthia Limited provides health services in Australia. It operates through three segments: Feet & Ankles; Bodies & Minds; and Eyes & Ears. The company operates podiatry and retail footwear; physiotherapy, hand therapy, occupational therapy, exercise physiology, and speech pathology clinics; and optometry and audiology stores, as well as manufactures and sells orthotic devices.
Healthia Fundamentals Summary
|HLA fundamental statistics|
Is HLA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HLA income statement (TTM)|
|Cost of Revenue||AU$147.45m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.025|
|Net Profit Margin||-1.66%|
How did HLA perform over the long term?See historical performance and comparison
Is HLA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 6/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HLA?
Other financial metrics that can be useful for relative valuation.
|What is HLA's n/a Ratio?|
Price to Sales Ratio vs Peers
How does HLA's PS Ratio compare to its peers?
|HLA PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
SLA SILK Laser Australia
AHX Apiam Animal Health
CAJ Capitol Health
ACL Australian Clinical Labs
Price-To-Sales vs Peers: HLA is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (1.2x).
Price to Earnings Ratio vs Industry
How does HLA's PE Ratio compare vs other companies in the AU Healthcare Industry?
Price-To-Sales vs Industry: HLA is good value based on its Price-To-Sales Ratio (1x) compared to the Australian Healthcare industry average (1.2x)
Price to Sales Ratio vs Fair Ratio
What is HLA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1x|
|Fair PS Ratio||1.1x|
Price-To-Sales vs Fair Ratio: HLA is good value based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).
Share Price vs Fair Value
What is the Fair Price of HLA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: HLA (A$1.47) is trading below our estimate of fair value (A$2.39)
Significantly Below Fair Value: HLA is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is Healthia forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HLA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).
Earnings vs Market: HLA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: HLA is expected to become profitable in the next 3 years.
Revenue vs Market: HLA's revenue (7.1% per year) is forecast to grow faster than the Australian market (3.6% per year).
High Growth Revenue: HLA's revenue (7.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HLA's Return on Equity is forecast to be low in 3 years time (11.2%).
Discover growth companies
How has Healthia performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HLA is currently unprofitable.
Growing Profit Margin: HLA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HLA is unprofitable, but has reduced losses over the past 5 years at a rate of 15.4% per year.
Accelerating Growth: Unable to compare HLA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HLA is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-7.9%).
Return on Equity
High ROE: HLA has a negative Return on Equity (0.2%), as it is currently unprofitable.
Discover strong past performing companies
How is Healthia's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: HLA's short term assets (A$27.5M) do not cover its short term liabilities (A$52.5M).
Long Term Liabilities: HLA's short term assets (A$27.5M) do not cover its long term liabilities (A$132.8M).
Debt to Equity History and Analysis
Debt Level: HLA's net debt to equity ratio (42.6%) is considered high.
Reducing Debt: Insufficient data to determine if HLA's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: HLA's debt is well covered by operating cash flow (22.3%).
Interest Coverage: HLA's interest payments on its debt are not well covered by EBIT (1.8x coverage).
Discover healthy companies
What is Healthia current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Forecast Dividend Yield
Dividend Yield vs Market
|Healthia Dividend Yield vs Market|
|Market Bottom 25% (AU)||2.8%|
|Market Top 25% (AU)||7.2%|
|Industry Average (Healthcare)||2.9%|
|Analyst forecast in 3 Years (Healthia)||4.0%|
Notable Dividend: Unable to evaluate HLA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HLA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HLA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HLA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: HLA is not paying a notable dividend for the Australian market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as HLA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Wesley James Coote, also known as Wes, B.Com., C.A., ACIS, serves as the Managing Director of Evolve Salons Limited. Mr. Coote has been Group Managing Director, Chief Executive Officer and Director at...
CEO Compensation Analysis
|Wes Coote's Compensation vs Healthia Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||AU$400k||AU$306k|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||AU$313k||AU$225k|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||n/a||n/a|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||AU$226k||AU$176k|
Compensation vs Market: Wes's total compensation ($USD259.45K) is about average for companies of similar size in the Australian market ($USD274.34K).
Compensation vs Earnings: Wes's compensation has increased whilst the company is unprofitable.
Experienced Management: HLA's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Experienced Board: HLA's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: HLA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|16 Sep 22||BuyAU$30,001||Darren Stewart||Individual||20,409||AU$1.47|
|16 Sep 22||BuyAU$5,088||Lisa Dalton||Individual||3,461||AU$1.47|
|16 Sep 22||BuyAU$60,000||Wesley Coote||Individual||40,816||AU$1.47|
|16 Sep 22||BuyAU$750,002||Glen Richards||Individual||510,205||AU$1.47|
|16 Sep 22||BuyAU$204,399||Paul Wilson||Individual||139,047||AU$1.47|
|16 Sep 22||BuyAU$59,976||Lisa Roach||Individual||40,800||AU$1.47|
|01 Sep 22||BuyAU$1,590,602||MAM Pty Limited||Company||986,657||AU$1.68|
|01 Sep 22||BuyAU$2,190,317||Wilson Asset Management (International) Pty Limited||Company||1,292,944||AU$1.69|
|16 May 22||BuyAU$8,088,580||Moelis Australia Asset Management Ltd||Company||4,322,273||AU$1.87|
|29 Apr 22||BuyAU$195,540||MAM Pty Limited||Company||107,350||AU$1.99|
|29 Apr 22||BuyAU$572,598||Wilson Asset Management (International) Pty Limited||Company||317,589||AU$1.80|
|17 Mar 22||BuyAU$3,072,135||MAM Pty Limited||Company||1,538,489||AU$2.07|
|17 Mar 22||BuyAU$6,193,467||Wilson Asset Management (International) Pty Limited||Company||3,190,373||AU$1.94|
|08 Mar 22||BuyAU$36,411||Paul Wilson||Individual||20,000||AU$1.94|
|04 Mar 22||SellAU$52,115||Darren Stewart||Individual||27,087||AU$1.93|
|16 Dec 21||BuyAU$63,790||Anthony Ganter||Individual||37,393||AU$2.25|
|19 Nov 21||BuyAU$100,001||Colin Kangisser||Individual||68,028||AU$1.47|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.5%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Healthia Limited's employee growth, exchange listings and data sources
- Name: Healthia Limited
- Ticker: HLA
- Exchange: ASX
- Founded: 2018
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: AU$198.502m
- Shares outstanding: 135.04m
- Website: https://www.healthia.com.au
- Healthia Limited
- East Tower
- Level 4
- Bowen Hills
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HLA||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Sep 2018|
|HLA||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Sep 2018|
|HE3||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Sep 2018|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/30 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.